ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - CDK4/6 Inhibitors

ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - CDK4/6 Inhibitors is organized by  i3 Health and will be held from Dec 07, 2022 - Dec 06, 2023.

Statement of Need:
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. These agents function by halting the cell cycle at the G1-to-S cell cycle checkpoint, blocking a cell division signaling cascade that is overexpressed in HR-positive/HER2-negative disease (Reddy et al, 2022). In this session, Constance Visovsky, Ph.D., RN, ACNP, FAAN, will clarify the mechanisms by which CDK4/6 inhibitors in combination with endocrine therapy are thought to hinder cancer progression, including the data that led to the approval of abemaciclib in the early-stage breast cancer setting. In addition, she will discuss strategies to identify side effects of CDK 4/6 inhibitors early and aggressively to minimize toxicity.

Learning Objectives:
Upon completion of this activity, participants should be able to
• Assess the indications and safety and efficacy profiles of novel CDK4/6 inhibitors
• Evaluate clinical tools for assessing and grading adverse events associated with novel CDK4/6 inhibitors
• Apply strategies to optimize the safety and tolerability of novel CDK4/6 inhibitors
• Develop educational strategies to help patients understand the benefits and risks of their breast cancer treatment plan

In this session, Constance Visovsky, PhD, RN, ACNP, FAAN, Director and the Lewis & Leona Hughes Endowed Chair of the College of Nursing at the University of South Florida, will clarify the mechanism by which CDK4/6 inhibitors in combination with endocrine therapy are thought to overcome resistance to endocrine therapy in ER-positive metastatic breast cancer, including the data that led to the approval of abemaciclib in the early-stage breast cancer setting, as well as early and aggressive identification of side effects to minimize toxicity.